Targeted Oncology

FDA Approves Label Update for Axi-Cel for R/R Primary CNS Lymphoma

The FDA has approved a label update for axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed autologous T-cell ...
Healio

Axi-cel CAR-T effective in patients with transplant-ineligible large B-cell lymphoma

Please provide your email address to receive an email when new articles are posted on . Axicabtagene ciloleucel demonstrated superior efficacy as second-line therapy compared with standard of care in ...
Medscape

FDA Updates Axi-Cel Safety Label for Large B-Cell Lymphoma

The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
Healio

Axi-cel exhibits durable benefit in advanced indolent non-Hodgkin lymphoma

Please provide your email address to receive an email when new articles are posted on . Axicabtagene ciloleucel induced durable responses for patients with relapsed or refractory indolent non-Hodgkin ...